Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Shares Bought by Teacher Retirement System of Texas

Teacher Retirement System of Texas boosted its position in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 60.3% in the 4th quarter, HoldingsChannel reports. The fund owned 65,415 shares of the biopharmaceutical company’s stock after acquiring an additional 24,615 shares during the period. Teacher Retirement System of Texas’ holdings in Lexicon Pharmaceuticals were worth $48,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the business. BNP Paribas Financial Markets lifted its position in Lexicon Pharmaceuticals by 71.2% in the third quarter. BNP Paribas Financial Markets now owns 31,853 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 13,246 shares during the last quarter. Arizona State Retirement System lifted its holdings in shares of Lexicon Pharmaceuticals by 34.4% in the 4th quarter. Arizona State Retirement System now owns 62,976 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 16,136 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in Lexicon Pharmaceuticals by 4.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,417,295 shares of the biopharmaceutical company’s stock valued at $2,225,000 after buying an additional 58,147 shares in the last quarter. Intech Investment Management LLC purchased a new position in shares of Lexicon Pharmaceuticals in the third quarter valued at $115,000. Finally, Atom Investors LP purchased a new stake in Lexicon Pharmaceuticals in the 3rd quarter valued at approximately $122,000. 74.70% of the stock is owned by hedge funds and other institutional investors.

Lexicon Pharmaceuticals Stock Performance

Shares of NASDAQ LXRX opened at $0.50 on Thursday. The business’s 50-day simple moving average is $0.59 and its 200-day simple moving average is $0.97. The company has a debt-to-equity ratio of 0.56, a quick ratio of 7.43 and a current ratio of 7.45. Lexicon Pharmaceuticals, Inc. has a 52 week low of $0.28 and a 52 week high of $2.45. The firm has a market cap of $123.88 million, a price-to-earnings ratio of -0.67 and a beta of 1.04.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings results on Thursday, March 6th. The biopharmaceutical company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.02. Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. The company had revenue of $26.55 million for the quarter, compared to the consensus estimate of $6.48 million. As a group, equities research analysts expect that Lexicon Pharmaceuticals, Inc. will post -0.66 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

LXRX has been the subject of a number of recent analyst reports. Leerink Partners reaffirmed a “market perform” rating and issued a $1.00 price objective (down previously from $2.00) on shares of Lexicon Pharmaceuticals in a research report on Tuesday, March 4th. Needham & Company LLC reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Monday, March 3rd. Leerink Partnrs lowered Lexicon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, March 5th. StockNews.com initiated coverage on Lexicon Pharmaceuticals in a report on Friday, March 28th. They set a “sell” rating on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $4.00 target price on shares of Lexicon Pharmaceuticals in a research report on Friday, March 28th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $3.67.

Lexicon Pharmaceuticals Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.